Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Can Peptides Help Sciatica: Research Protocols vs Marketing Claims

BPC-157 TNF-alpha downregulation, NF-kB inhibition, angiogenesis 250–500 mcg subcutaneous daily Multiple animal models, limited human RCTs Strongest preclinical evidence for nerve compression inflammation Thymosin Beta-4 VEGF upregulation, endothelial migratio

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • BPC-157
  • TNF-alpha downregulation, NF-kB inhibition, angiogenesis
  • 250–500 mcg subcutaneous daily
  • Multiple animal models, limited human RCTs
  • Strongest preclinical evidence for nerve compression inflammation
  • Thymosin Beta-4
  • VEGF upregulation, endothelial migration, tissue repair
  • 2–5 mg subcutaneous twice weekly
  • Human tissue repair studies (tendon, muscle)
  • Indirect evidence via vascular repair mechanisms
  • Cerebrolysin
  • NGF/BDNF mimetic, axonal regeneration support
  • 10–30 ml intramuscular 3x/week
  • Human neuropathy trials show nerve conduction improvement
  • Direct evidence in peripheral nerve pathology
  • KPV
  • NF-kB inhibition, IL-6/IL-8 suppression
  • 500 mcg–2 mg subcutaneous daily
  • Human IBD and dermatology trials
  • Established anti-inflammatory profile, untested in sciatica
  • Dihexa
  • HGF receptor activation, synaptogenesis
  • 1–5 mg oral daily (research contexts)
  • Animal models only, no human peripheral nerve data
  • Theoretical benefit via neural repair pathways
  • The critical distinction: peptides help sciatica when they address the inflammatory biology at the nerve root. Not when they're marketed as generic 'pain relief.' BPC-157 and TB-500 have the strongest mechanistic rationale because they target the specific pathology (cytokine-driven inflammation and ischemic tissue damage) that keeps sciatica chronic. Cerebrolysin shows direct human evidence in peripheral neuropathy contexts. KPV and Dihexa have plausible mechanisms but lack sciatica-specific trials.